Global Toxocariasis Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Toxocariasis Treatment Market Analysis

The toxocariasis treatment market is evolving significantly, driven by increasing awareness, advancements in diagnostics, and the development of targeted therapies. Toxocariasis, a parasitic infection caused by Toxocara species, presents with symptoms such as fever, abdominal pain, and vision problems. As the prevalence of zoonotic infections rises globally, demand for effective diagnostic and therapeutic solutions is growing. Advanced diagnostic tools, such as enhanced blood tests and molecular assays, have improved early and accurate detection of the disease, enabling timely treatment interventions. The market is witnessing innovations in treatment options, including the development of more effective anthelmintics and corticosteroids to manage severe cases. Additionally, research into anti-inflammatory therapies and immunomodulators is providing hope for addressing complications such as ocular and neurological toxocariasis. Governments and private players are investing heavily in R&D to combat neglected parasitic diseases such as toxocariasis, further boosting the market. Improved healthcare infrastructure, particularly in emerging regions, is expanding access to treatment, while advancements in oral and intravenous drug formulations enhance patient compliance. With a growing focus on zoonotic disease management and preventive healthcare, the toxocariasis treatment market is poised for sustained growth and innovation.

Toxocariasis Treatment Market Size

The global toxocariasis treatment market size was valued at USD 257.65 million in 2024 and is projected to reach USD 420.87 million by 2032, with a CAGR of 6.33% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Toxocariasis Treatment Market Trends

“Increasing Adoption of Personalized Medicine”

The toxocariasis treatment market is witnessing a growing trend of personalized medicine driven by advancements in diagnostic tools and targeted therapies. Molecular diagnostics, such as polymerase chain reaction (PCR) assays, are enabling more precise identification of Toxocara species, which helps in tailoring treatments to specific patient needs. This trend is complemented by innovations in drug development, including enhanced formulations of anthelmintics such as albendazole, which offer improved efficacy and reduced side effects. For instance, advanced oral therapies with controlled release mechanisms are gaining popularity, improving patient compliance and outcomes. Additionally, the focus on addressing complications such as ocular and neurological toxocariasis through anti-inflammatory drugs and immunomodulators underscores the market's progression toward comprehensive care. The integration of these technologies with telemedicine platforms further supports timely diagnosis and treatment, particularly in underserved regions. This trend highlights the market's shift towards precision medicine and its potential to address the global burden of toxocariasis effectively.

Report Scope and Toxocariasis Treatment Market Segmentation     

Toxocariasis Treatment Market Definition

Toxocariasis treatment refers to the medical management of an infection caused by the parasitic roundworms Toxocara canis (from dogs) or Toxocara cati (from cats). Treatment typically involves the use of anthelmintic medications, such as albendazole or mebendazole, to kill the parasites. In severe cases, corticosteroids may be prescribed to reduce inflammation, especially for complications such as ocular toxocariasis (affecting the eyes) or visceral larva migrans (affecting internal organs). The goal of toxocariasis treatment is to eliminate the parasite, manage symptoms, and prevent long-term damage caused by inflammation or tissue invasion.

Toxocariasis Treatment Market Dynamics

Drivers

• Increasing Prevalence of Zoonotic Parasitic Infections

The increasing prevalence of zoonotic parasitic infections, such as toxocariasis, is a significant market driver, particularly in regions with high pet ownership and inadequate sanitation. Toxocara species, which are primarily transmitted through contaminated soil or pet feces, cause widespread infections, particularly in children. According to the World Health Organization (WHO), over 1 billion people globally are at risk of helminthic infections, with toxocariasis being a common but often underdiagnosed disease. Studies have shown that areas with high stray animal populations and poor hygiene practices are more susceptible to Toxocara exposure. For instance, research conducted in urban areas of Latin America and Southeast Asia has demonstrated that environmental contamination by Toxocara eggs is prevalent, leading to a higher incidence of the disease. This surge in parasitic infections is driving demand for effective treatment solutions, including anthelmintics and supportive therapies, which are essential to managing toxocariasis and reducing its long-term complications, such as ocular damage. As awareness and detection improve, the growing global burden of parasitic diseases highlights the expanding opportunity for the toxocariasis treatment market​

• Rising Healthcare Awareness and Increased Access to Medical Services

Rising healthcare awareness and increased access to medical services are significant drivers of the toxocariasis treatment market. As knowledge about parasitic diseases such as ocular toxocariasis and visceral larva migrans grows, more individuals are seeking medical attention for these conditions. This is particularly true in regions with increasing healthcare infrastructure and public health initiatives. According to the Centers for Disease Control and Prevention (CDC), awareness campaigns targeting parasitic infections and zoonotic diseases are critical in educating the public about the risks and symptoms of toxocariasis. For instance, in the U.S., public health efforts have led to higher diagnostic rates of toxocariasis, especially in children, who are more vulnerable to infections from pet feces or contaminated soil. As healthcare access improves, particularly in developing nations, the demand for effective treatments such as anthelmintics, corticosteroids, and diagnostic tests is rising. This growing awareness drives market growth and underscores the need for better detection methods and therapeutic solutions to manage the complications of toxocariasis.

Opportunities

• Growing Advancements in Diagnostic Technologies

Advancements in diagnostic technologies have opened significant market opportunities for the toxocariasis treatment sector by improving the accuracy and speed of detection. Tests such as enzyme-linked immunosorbent assay (ELISA) test and polymerase chain reaction (PCR) have revolutionized the diagnosis of toxocariasis, allowing for earlier identification of Toxocara infections. These technologies enable healthcare providers to detect the presence of the parasite in patients more reliably, even at subclinical stages. For instance, PCR assays are increasingly used to identify the genetic material of Toxocara species in clinical samples, providing high sensitivity and specificity. Early diagnosis leads to timely and effective treatment, including the use of anthelmintics such as albendazole and mebendazole, which helps prevent the progression of severe complications such as ocular toxocariasis or neurological damage. With the growing focus on early detection and personalized treatment approaches, advancements in diagnostics present a major market opportunity, particularly in regions with rising healthcare investments and increasing awareness of parasitic disease.

• Increasing Government and NGO Support

Government and NGO support play a critical role in raising awareness and improving access to diagnostics and treatment options for toxocariasis, especially in endemic regions. Increased public health investments, such as funding for awareness campaigns, treatment programs, and healthcare infrastructure, have contributed to early detection and better disease management. For instance, the World Health Organization (WHO) and local health agencies have launched initiatives targeting parasitic diseases, including toxocariasis, to educate the public on preventive measures and ensure that individuals with symptoms receive timely treatment. In regions such as Southeast Asia and Latin America, where toxocariasis is more prevalent, NGOs are also involved in community outreach and offering subsidized treatments. This growing support from governments and non-governmental organizations opens up significant market opportunities for diagnostic companies, pharmaceutical firms, and healthcare providers to expand their reach, improve patient outcomes, and increase demand for targeted therapies and diagnostic technologies.

Restraints/Challenges

• High Cost of Treatment for Toxocariasis

The high cost of treatment for toxocariasis poses a significant challenge to the market, particularly in low- and middle-income countries. While medications such as albendazole and mebendazole are commonly used to treat Toxocara infections, the cost of these drugs, along with the need for advanced diagnostic tools such as PCR or ELISA tests, can be prohibitive for many patients, especially in underserved regions. For instance, in some developing countries, the cost of a complete treatment regimen for toxocariasis can exceed the average monthly income, limiting patient access to necessary care. Additionally, treatments for severe cases, such as ocular toxocariasis, may require long-term management with corticosteroids, further adding to the cost burden. This financial barrier, combined with the limited availability of healthcare resources in endemic areas, makes it difficult for many to receive timely and effective treatment. Consequently, the high cost of treatment remains a key market challenge, hindering the widespread adoption of available therapies and slowing efforts to reduce the global burden of the disease

• Side Effects Associated with Medications

Side effects associated with medications used in the treatment of toxocariasis, such as albendazole and mebendazole, represent a significant market challenge. While these anthelmintic drugs are effective in killing the Toxocara larvae, they can cause adverse reactions, including nausea, abdominal pain, and headaches. In more severe cases, long-term use of corticosteroids, which are prescribed for complications such as ocular toxocariasis, can lead to side effects such as weight gain, diabetes, and increased susceptibility to infections. These side effects may discourage patient compliance, particularly in children or those with pre-existing health conditions, and limit the widespread use of these drugs. For instance, the use of albendazole can lead to liver toxicity in some cases, which necessitates close monitoring, further complicating treatment protocols. As a result, the challenge of managing side effects affects patient outcomes and places an additional burden on healthcare systems, as it may require prolonged medical oversight and the use of complementary therapies. This concern around adverse effects, alongside the limited range of treatment options, makes the development of safer and more effective therapies crucial to improving market dynamics and treatment success rates.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Toxocariasis Treatment Market Scope

The market is segmented on the basis of treatment, diagnosis, dosage, route of administration, symptoms, end-users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Anthelmintics
• Corticosteroids
• Anti-inflammatory Drugs
• Surgery
• Others

Diagnosis

• Blood Tests
• Laboratory Tests
• Others

Dosage Forms

• Tablet
• Injection
• Others

Route of Administration

• Oral
• Intravenous
• Others

Symptoms

• Fever
• Headache
• Swollen Glands
• Belly Pain
• Wheezing
• Vision Problems
• Seizures
• Loss of Appetite
• Rashes
• Enlarged Liver
• Others

End-Users

• Clinic
• Hospital
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Toxocariasis Treatment Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, treatment, diagnosis, dosage, route of administration, symptoms, end-users, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the toxocariasis treatment market, driven by the presence of major pharmaceutical companies actively developing innovative therapies and conducting robust research and development (R&D) activities. The region benefits from high disposable income levels, enabling greater access to advanced healthcare services and treatments. Additionally, North America's high healthcare expenditure supports the availability of cutting-edge diagnostic tools and treatment options for parasitic infections such as toxocariasis. A well-established healthcare infrastructure further enhances the management of the disease, making the region a hub for ongoing advancements and investments in this field.

Asia-Pacific is anticipated to witness significant growth in the toxocariasis treatment market during the forecast period of 2025-2032, driven by increasing investments in research and development activities. Emerging economies in the region are focusing on enhancing healthcare infrastructure, which supports the development and availability of advanced diagnostic and treatment options. Additionally, rising investments in the healthcare sector by both public and private entities are fueling market expansion, as access to medical services and innovative therapies improves. Strong government support, including funding for healthcare programs and awareness campaigns about parasitic diseases, further bolsters the region’s growth potential, making Asia-Pacific a promising market for toxocariasis treatment advancements.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Toxocariasis Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Toxocariasis Treatment Market Leaders Operating in the Market Are:

• Merck KGaA (Germany)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Sanofi (France)
• Cipla Inc. (India)
• AstraZeneca (U.K.)
• Johnson & Johnson Services, Inc. (U.S.)
• Viatris Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Astellas Pharma Inc. (Japan)
• Bristol-Myers Squibb Company (U.S.)
• Novartis AG (Switzerland)
• Accord Healthcare (U.K.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• AbbVie Inc. (U.S.)
• Abbott (U.S.)
• Bayer AG (Germany)
• Sumitomo Corporation (Japan)
• LEO Pharma A/S (Denmark)
• Bausch Health Companies Inc. (Canada)
• Assertio Holdings, Inc. (U.S.)
• Boehringer Ingelheim International GmbH (Germany)
• Amgen Inc. (U.S.)

SKU-66670